Page 60 - Eceptor News Today

A team of international scientists has recently characterized the structure of tumor necrosis factor receptor associated factor 6 (TRAF6) N-terminal domain for therapeutic purposes.

Researchers assessed T-cell tolerance checkpoints observed in atherosclerosis.

After more than two years since its discovery, six million deaths, and half a billion reported cases, there is still no effective cure for COVID-19. Even though vaccines have lowered the impact of outbreaks, patients that contract the disease can only receive supportive care while they wait for their own body to clear the infection.

A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.

Researchers presented the coronavirus vaccines research and development roadmap to promote the development of broadly protective COVID-19 vaccines.

The University of Vermont Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy beginning in February, when final accreditation and approval to begin treating patients is expected.

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

Researchers reported that some monoclonal nAbs directed against distinct RBD epitopes nested inside the SARS-CoV-2 S could substitute ACE2 as a receptor and support fusion between viral and host cell membranes facilitating viral infectivity.

A retrovirus known as human T-cell lymphotropic virus type 1 (HTLV-1) is known to cause a number of diseases, including inflammatory diseases of the eye. Recently, researchers in Japan have investigated an antibody treatment for inflammatory eye disease in ocular cells infected with HTLV-1.

Positive Phase 1 clinical results published in 'The Journal of Immunology' (online) Two ongoing Phase 2 clinical trials in Ulcerative Colitis and primary Sjögren's Syndrome Positive